Cross-species-specific single domain bispecific single chain antibody

US11987633B2 · kind B2 · utility

Assignee

• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Peter Kufer · Munich, DE
• Tobias Raum · Munich, DE
• Roman Kischel · Munich, DE
• Ralf Lutterbüse · Munich, DE
• Patrick Hoffmann · Munich, DE
• Matthias Klinger · Gilching, DE
• Doris Rau · Munich, DE
• Susanne Mangold · Munich, DE

Key dates

• Filing date: Mar 17, 2021
• Grant date: May 21, 2024
• Expiry date: Oct 11, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/34
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical composition…